Mixed connective tissue disease: state of the art on clinical practice guidelines

Benjamin Chaigne,1 Carlo Alberto Scirè,2 Rosaria Talarico,2 Tobias Alexander,4 Zahir Amoura,5 Tadej Avci,6 Lorenzo Beretta7 Andrea Doria,8 Aurelien Guffroy,9 Vera Guimarães,10 Eric Hachulla,11 Thomas Krieg,12 David Launay,11 Gemma Lepri,13 Pia Moinzadeh,12 Ulf Müller-Ladner,14 Simona Rednic,15 Ana Rodrigues,16 Sander W Tas,17 Ronald F Van Vollenhoven,18 Ana Vieira,19 Stefano Bombardieri,20 João Eurico Fonseca,21 Ilaria Galetti,22 Matthias Schneider,23 Vanessa Smith,24,25 Maurizio Cutolo,26 Marta Mosca,3 Rebecca Fischer-Betz23

ABSTRACT

Mixed connective tissue disease (MCTD) is a complex overlap disease with features of different autoimmune connective tissue diseases (CTDs) namely systemic sclerosis, poly/dermatomyositis and systemic lupus erythematosus in patients with antibodies targeting the U1 small nuclear ribonucleoprotein particle. In this narrative review, we summarise the results of a systematic literature research which was performed as part of the European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal Diseases project, aimed at evaluating existing clinical practice guidelines (CPGs) or recommendations. Since no specific CPGs on MCTD were found, other CPGs developed for other CTDs were taken into consideration in order to discuss what can be applied to MCTD even if designed for other diseases. Three major objectives were proposed for the future development of CPGs: MCTD diagnosis (diagnostic criteria), MCTD initial and follow-up evaluations, MCTD treatment. Early diagnosis, epidemiological data, assessment of burden of disease and QOL aspects are among the unmet needs identified by patients.

INTRODUCTION

Mixed connective tissue disease (MCTD) was initially described by Sharp et al.1 MCTD was first reported as a mild overlap disease with features of different autoimmune connective tissue diseases (CTDs) namely systemic sclerosis, poly/dermatomyositis and systemic lupus erythematosus in patients with antibodies targeting the U1 small nuclear ribonucleoprotein particle (U1 snRNP).

Since the initial description, the definition as an independent clinical entity has been discussed, especially since patients with U1 snRNP may meet the classification criteria of other ‘defined’ CTDs in the course of time.2,3 Also, the initial description by Sharp of MCTD as benign disease without organ involvement and with prompt response to low-dose glucocorticoids4 has not been confirmed in all studies. In addition, there are no generally accepted classification criteria.5 Nevertheless, some particularities, for example, pulmonary disease, point to an independent disease pattern.

Clinical practice guidelines (CPGs) are defined as ‘systematically developed statements to assist practitioner and patient decisions about healthcare for specific clinical circumstances’2 and are made to optimise patient care. With regard to CTDs, CPGs should be based on medical high-level evidence and integrate as many themes as possible of each CTD, that is, diagnosis, patients management, treatment, prognosis and complications. In that matter, the European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal Diseases (ERN ReCONNET)
launched a cooperative effort to review the existing CPGs on CTDs.

The objective of this review is to identify and evaluate the available CPGs providing specific evidence-based medicine (EBM) recommendations for MCTD.

METHODS
Source and search strategy
We carried out a systematic search in PubMed and EMBASE based on controlled terms (MeSH and Emtree) and keywords of the disease and publication type (CPGs). We reviewed all the published articles in order to identify existing CPGs on diagnosis, monitoring and treatment, according to the Institute of Medicine 2011\(^3\) definition (CPGs are statements that include recommendations intended to optimise patient care that are informed by a systematic review of evidence and an assessment of the benefits and harms of alternative care options\(^3\)).

The disease coordinator of the ERN-ReCONNET for MCTD has assigned the work on CPGs to the healthcare providers (HCPs) involved. Moreover, in order to implement the list of guidelines provided by MEDLINE and Embase search, the group also performed a hand search. A first screening among papers included in the final list (systematic search+hand search) based on title and abstract selected EBM guidelines to be assessed. A general assessment of the CPGs has been performed following the Appraisal of Guidelines for Research and Evaluation (AGREE) II tool checklist, not for formal appraisal but only to inform discussion.\(^1\)-\(^6\) A discussion group was set for the evaluation of the existing CPGs and to identify the unmet needs.

Summary of the search strategy

State of the art on CPGs
Absence of specific recommendations/guidelines for MCTD
The state of the art on CPGs in MCTD is presented in figure 1. A systematic Embase/MEDLINE search identified 124 references to be screened and analysed by the ERN ReCONNET MCTD group. After screening and full-text analysis, five references were selected.\(^7\)-\(^11\) After final evaluation, no reference was selected as specific CPG for MCTD.

Combined recommendations
Although there was no specific CPG on MCTD, the ERN-ReCONNET MCTD group selected five references that could be used in the context of MCTD. These references were common to other CTD such as systemic sclerosis or vasculitis and included recommendations for the testing of anti-Sm and anti-RNP antibodies,\(^7\) for screening pulmonary arterial hypertension,\(^8\) for the assessment of autoantibodies to cellular antigens referred to as antinuclear antibodies,\(^9\) for the management of skin ulcers,\(^10\) and for using cardiovascular MR.\(^11\)

Unmet needs
This is the first review providing an overview of currently available CPGs for MCTD. We did not identify specific CPGs addressing important issues in MCTD. Efficient and effective guidelines improve patient care and help medical practice and decision-making.\(^12\) Therefore, the ERN-ReCONNET MCTD group agrees on the general need for specific recommendations for MCTD. To prioritise what should be done in the matter of MCTD, three major objectives were proposed for CPGs future development:

1. CPGs on MCTD diagnosis (diagnostic criteria):
   Although different sets of clinical criteria have been proposed, there is no consensus about the most accurate one.\(^3\) MCTD often resembles several conditions and yet can easily be misdiagnosed by numerous rheumatic conditions including systemic sclerosis, rheumatoid arthritis or so-called overlap syndromes. Without
a standardised and acknowledged set of criteria, an agreement regarding MCTD existence and disease CPGs is not possible. Moreover, such classification criteria would facilitate the establishment of registers to collect a meaningful number of patients with MCTD to evaluate the course and prognosis. The classification criteria would also enable to evaluate the role of biomarkers, specifically the potential diagnostic/prognostic role of antibodies targeting U1 snRNP and/or in combination with the detection of autoantibodies that could earlier characterise more defined CTDs such as anti-SCL70, anti-CCP, anti-Jo1, antiSm, anti-dsDNA-associated entities for defining early progression.

2. CPGs on MCTD initial and follow-up evaluations: At present, the initial approach, the type and the frequency of follow-up assessments of patients with MCTD are often handled very differently or performed according to the management of other rheumatic diseases. On one hand, MCTD is described as a potentially mild and often treatable condition. On the other hand, the disease is incurable and can be deleterious or even life-threatening with development of pulmonary, kidney, gastrointestinal and central nervous system involvement. Here, early and targeted intervention will definitively be associated with a better outcome. The worst prognosis and high mortality are associated with the presence of pulmonary disease. To improve management, it would certainly be helpful to develop and validate a (composite) disease activity score for MCTD that takes into account all relevant signs and symptoms. Agreement on the frequency of follow-up assessments during the course of disease on the basis of guidelines would facilitate the management of patients for clinicians.

3. CPGs on MCTD treatment: There is no agreement about the initial or long-term treatment of MCTD, especially on the usefulness of low-dose glucocorticoids, antimalaria and immunosuppressive therapies in various clinical situations. To date, there has been no randomised controlled trial in MCTD. Usually, patients with MCTD are treated based on similarities with other CTDs or based on organ-based management. Classification criteria would therefore also enable to perform clinical trials on therapeutic interventions. In addition, the management of comorbidities (such as osteoporosis, atherosclerosis, etc) and specific situations (such as pregnancy, family planning, etc) should be addressed. Overall, the ERN-ReCONNET MCTD group agrees on the need for evidence-based CPGs on MCTD treatment. Such guidelines undoubtedly require careful data collection from a larger number of patients and collaboration between experts and registers from different countries.

Last but not the least, CPGs on MCTD should also take into account patients’ point of view in order to improve patients’ daily quality of care and life. Patient-reported outcomes for patients with MCTD should therefore be developed and evaluated.

**Patients’ unmet needs**

This paragraph intends to highlight the unmet needs of the MCTD community. The content of this paragraph
has been realised by the ERN ReCONNET European Patient Advocacy Group that carefully collected the voices and the points of view of the whole European community of the disease they represent.

Early diagnosis is the primal need for patients with MCTD as it often takes a long time to establish the diagnosis. Besides that, when a diagnosis is finally made, patients are traditionally vaguely told that they have ‘some kind of’ rheumatic disease or autoimmune disease which clearly does not help understanding what is wrong with them and what they are expected to face during the lifelong course of the disease. The understanding how this disease develops and what outcomes are realistic for these patients, is essential.

Furthermore, prevalence of the disease is not well defined, and patients and doctors have no precise information on the number of MCTD cases at present. Eventually, the European Reference Networks will be able to help somehow with the most fundamental measure of the burden of the disease to plan appropriately for patient healthcare needs. Also, there’s a lack of knowledge regarding this disease among physicians as patients often feel that they do not know how to address the reported symptoms.

Life style and its impact in patients quality of life (QOL) is often disregarded, thus the need to measure it or understand if it is ever measured would be useful to build evidence-based patient-focused guidelines on lifestyle issues. There is also a need for a more holistic approach to disease management, as doctors may be treating symptoms and organ to organ, while overlooking the individual beyond the patient. Patient education may also contribute to improve QOL.

In addition, pain management and fatigue are huge challenge, as pain is still treated insufficiently, and fatigue is still inadequately assessed. Non-pharmacological approaches and specific programme, such as exercise, patient education, psychological support or emotional burden management, are needed.

Treatment options are limited to hydroxychloroquine, corticosteroids and immunosuppressive drugs, so there is also a need for alternative treatments with less side effects.

Information and awareness are undoubtfully very important unmet needs among all stakeholders involved: HCPs, public, employers, families, care givers and patients. Furthermore, information on available clinical trials is missing so there is definitely a gap to fill.

Last but not least, tax exemption on access to care needs reflection, as we need to understand how it works in different European countries.

CONCLUSIONS

This review highlights the absence of specific CPG on MCTD. There is a need for high-quality evidence-based guidelines to assist practitioner and patient decisions about MCTD healthcare. Further CPGs should focus on MCTD diagnosis, evaluations, treatment and patients’ needs. International registries are particularly important to collect solid data that can serve as input for CPGs.

Author affiliations
1Service de Médecine Interne, Hôpital Cochin, Centre de Référence Maladies systématiques Auto-immunes Rares d’Île de France, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Descartes, Paris, France
2Section of Rheumatology, Department of Medical Sciences, University of Ferrara, Ferrara, Italy
3Rheumatology Unit, AOU Pisana, Pisa, Italy
4Department of Rheumatology and Clinical Immunology, Charité University Hospital Berlin, Berlin, Germany
5Department of Internal Medicine, Hospital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France
6Department of Allergology Rheumatology and Clinical Immunology, University Children’s Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia
7Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy
8Rheumatology Unit Department of Medicine, AO Padova and University of Padua, Padua, Italy
9Service de rhumatologie Hôpitaux Universitaires de Strasbourg, Centre National de Référence des Maladies Systémiques et Auto-Immunes Rares Grand-Est Sud-Ouest, Strasbourg, France
10Liga Portuguesa Contra as Doencas Reumaticas, Lisbon, Portugal
11Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Systémiques et Auto-Immunes Rares du Nord-Ouest, Lille, France
12Department of Dermatology, Universitätsklinikum Köln, Cologne, Germany
13Division of Rheumatology and Scleroderma Unit, Department of Clinical and Experimental Medicine AOU Careggi, University of Florence, Florence, Italy
14Department of Rheumatology and Clinical Immunology, Kerckhoff Klinik, Justus-Liebig University of Giessen, Bad Nauheim, Germany
15Department of Rheumatology, Emergency County Teaching Hospital, Cluj-Napoca, Romania
16Centro Hospitalar de Lisboa Central, Lisbon, Portugal
17Amsterdam Rheumatology & Immunology Center (ARC), Academic Medical Center, Amsterdam, The Netherlands
18Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands
19Liga Portuguesa Contra as Doencas Reumaticas, Núcleo Síndrome de Sjögren, Lisbon, Portugal
20University of di Pisa, Pisa, Italy
21Rheumatology Department Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon Academic Medical Centre, Lisbon, Portugal
22FESCA, Federation of European Scleroderma Associations, Milan, Italy
23Department of Rheumatology, Universitätsklinikum Düsseldorf, Düsseldorf, Germany
24Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
25Department of Internal Medicine, Ghent University, Ghent, Belgium
26Research Laboratory and Academic Division of Clinical Rheumatology Department of Internal Medicine, IRCCS Polyclinic Hospital San Martino, University of Genoa, Genoa, Italy

Acknowledgements Thanks to all the members of the Steering Committee of the ERN ReCONNET for the huge commitment during this work. A special thank goes to all the members of the ERN ReCONNET team for providing support during all the phases of the Work Package 3.

Contributors CB, SCA, TR, MM and F-BR: substantial contributions to the conception and design of the work; the acquisition, analysis and interpretation of data; drafting the work and revising it critically for important intellectual content; final approval of the version to be published; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. ATa, AZ, AFA, BL, DA, GA, GV, HÉ, KT, LD, LG, MF, M-LU, RS, RA, TSW, VRF, VA: substantial contributions to the analysis and interpretation of data; final approval of the version to be published; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. BS, FJE, GI, SM, SV, CM: revising the
work critically for important intellectual content; final approval of the version to be published; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Funding** This publication was funded by the European Union’s Health Programme (2014-2020).

**Disclaimer** ERN ReCONNET is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Commission. The content of this publication represents the views of the authors only and it is their sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains.

**Competing interests** None declared.

**Patient consent** Not required.

**Provenance and peer review** Commissioned; externally peer reviewed.

**Data sharing statement** No additional data are available.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0

**REFERENCES**

